ASXL1 and colorectal carcinoma: Initial studies focused on sequencing assays demonstrate that CHIP affects mutations in genes that are known to be implicated in haematological malignancies, such as TET2, DNMT3, JAK2 and ASXL1, without much relevance to solid tumours such as CRC.